Director change at LifeStance (NASDAQ: LFST) and RSU grant

Rhea-AI Filing Summary

LifeStance Health Group reported a change in its board of directors. On August 19, 2025, William Miller resigned from the board and all its committees, effective immediately, and the company states his resignation was not due to any disagreement with the company. On August 20, 2025, the board appointed Sarah Personette as a new director.

In connection with her appointment, and under the company’s 2021 Equity Incentive Plan, Ms. Personette received an initial grant of 74,766 restricted stock units. These RSUs will vest based on time and performance conditions, subject to her continued service on the board.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

false 0001845257 0001845257 2025-08-19 2025-08-19

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 19, 2025

LifeStance Health Group, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware		001-40478		86-1832801
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

4800 N. Scottsdale Road
Suite 2500
Scottsdale, Arizona		85251
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: 425 279-8500

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.01 per share		LFST		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On August 19, 2025, William Miller notified the LifeStance Health Group, Inc. (the “Company”) board of directors (the “Board”) of his resignation from the Board and all of its committees, effective immediately. The resignation is not a result of any disagreement between Mr. Miller and the Company.

In connection with Mr. Miller’s resignation, on August 20, 2025, the Board appointed Sarah Personette as a director of the Company. In connection with her appointment, pursuant to the Company’s 2021 Equity Incentive Plan, Ms. Personette received an initial award of 74,766 restricted stock units that will vest according to the terms of a time-and performance-based restricted stock unit agreement, subject to Ms. Personette’s continued service on the Board.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				LIFESTANCE HEALTH GROUP, INC.
Date: August 22, 2025				By:		/s/ Ryan Pardo
				Name:		Ryan Pardo
				Title:		Chief Legal Officer and Secretary

FAQ

What board change did LifeStance Health Group (LFST) disclose?

LifeStance Health Group disclosed that William Miller resigned from its board and all board committees, and that Sarah Personette was appointed as a new director.

Did William Miller resign from LifeStance Health Group (LFST) over a disagreement?

The company states that William Miller’s resignation from the board was not the result of any disagreement between him and LifeStance Health Group.

Who is the new director appointed to LifeStance Health Group (LFST)’s board?

The board of LifeStance Health Group appointed Sarah Personette as a director following William Miller’s resignation.

What equity award did Sarah Personette receive from LifeStance Health Group (LFST)?

In connection with her appointment, Sarah Personette received an initial award of 74,766 restricted stock units under the company’s 2021 Equity Incentive Plan.

How will Sarah Personette’s restricted stock units at LFST vest?

Her 74,766 restricted stock units will vest according to a time- and performance-based restricted stock unit agreement, subject to her continued service on the board.

When did LifeStance Health Group (LFST) appoint Sarah Personette to its board?

LifeStance Health Group’s board appointed Sarah Personette as a director on August 20, 2025.

Under which plan was the RSU grant to Sarah Personette at LFST made?

The restricted stock unit grant to Sarah Personette was made under LifeStance Health Group’s 2021 Equity Incentive Plan.